Related Experiment Video
Updated: Jun 28, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate
Hsi-Huei Lu1, Nan-Tsing Chiu1, Mu-Hung Tsai2
1Division of Nuclear Medicine, Department of Medical Imaging, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
Prostate-specific antigen doubling time (PSADT) changes can predict survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223). Monitoring PSADT during therapy offers a valuable tool for assessing treatment effectiveness.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Prostate Cancer Research
Background:
- Radium-223 (Ra-223) is a key treatment for bone-dominant metastatic castration-resistant prostate cancer (mCRPC).
- Effective markers for monitoring Ra-223 treatment response in mCRPC are lacking.
- Prostate-specific antigen doubling time (PSADT) is a potential surrogate marker for treatment efficacy.
Purpose of the Study:
- To investigate prostate-specific antigen doubling time (PSADT) as a marker for assessing Ra-223 treatment response in mCRPC patients.
- To evaluate the association between dynamic PSADT changes and overall survival.
Main Methods:
- Retrospective analysis of 35 mCRPC patients treated with radium therapy.
- Calculation of baseline and interim PSADT from prostate-specific antigen (PSA) measurements.
- Cox proportional hazards model used for univariable and multivariable analysis of overall survival.
Main Results:
- Median overall survival was 13.3 months.
- PSA dynamic response (improved PSADT or decreased PSA) observed in 20 patients (57.1%).
- PSA dynamic response was significantly associated with improved overall survival (HR=0.318, p=0.010).
Conclusions:
- Dynamic changes in PSADT correlate with survival outcomes in mCRPC patients undergoing Ra-223 therapy.
- Comparing interim and baseline PSADT can serve as a valuable marker for treatment benefit assessment.
- PSADT monitoring may aid in personalized treatment strategies for mCRPC.
